# Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

> **NCT04553393** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Decitabine
- **DRUG:** Chidamide and Decitabine
- **BIOLOGICAL:** Decitabine-primed Tandem CAR19/20 engineered T cells

## Key facts

- **NCT ID:** NCT04553393
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-09
- **Primary completion:** 2021-09-08
- **Final completion:** 2022-09-08
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2020-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04553393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04553393, "Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04553393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*